26 results on '"Carboxypeptidases immunology"'
Search Results
2. [Prostate specific membrane antigen (PSMA) as a role of tumor marker].
- Author
-
Saito S, Horiguchi Y, and Murai M
- Subjects
- Antibodies, Monoclonal, Carboxypeptidases immunology, DNA, Genetic Therapy, Glutamate Carboxypeptidase II, Humans, Male, Prostatic Neoplasms therapy, Antigens, Surface, Biomarkers, Tumor blood, Carboxypeptidases blood, Prostatic Neoplasms diagnosis
- Published
- 2002
3. Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles.
- Author
-
Nelson PS
- Subjects
- Acid Phosphatase, Carboxypeptidases immunology, Gene Expression Profiling, Glutamate Carboxypeptidase II, Humans, Male, Oligonucleotide Array Sequence Analysis, Prostate-Specific Antigen immunology, Prostatic Neoplasms immunology, Protein Tyrosine Phosphatases immunology, Testosterone Congeners pharmacology, Antigens, Surface, Immunotherapy methods, Prostatic Neoplasms genetics, Prostatic Neoplasms therapy
- Abstract
Carcinoma of the prostate represents one of the most frequently diagnosed cancers in men. If detected at an early stage, prostate cancer is highly treatable. However, cancers identified at a late stage are rarely cured with contemporary medical therapies. Early detection strategies presently center on the identification of prostate-specific proteins in the serum, and emerging therapeutics have utilized genes and proteins with prostate-restricted expression for tissue-selective immunological regimens incorporating vaccines, dendritic cell therapy, gene therapy, and antibody-based cell targeting. In order to develop improved therapeutic procedures, efforts have been directed toward the identification of genes exhibiting prostate-restricted expression profiles, or altered expression levels in neoplastic cells relative to their normal counterparts. Comprehensive expression profiling approaches such as the analysis of oligonucleotide- or complementary DNA (cDNA)-microarrays have greatly enhanced these efforts. Genes and their cognate proteins identified using such methods offer additional diagnostic and therapeutic targets that may aid in the understanding and treatment of prostate carcinoma.
- Published
- 2002
- Full Text
- View/download PDF
4. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.
- Author
-
Lu J and Celis E
- Subjects
- Algorithms, Cancer Vaccines immunology, Epitopes, T-Lymphocyte immunology, Glutamate Carboxypeptidase II, HLA-A2 Antigen immunology, Humans, Immunotherapy, Adoptive methods, Male, Oligopeptides immunology, Oligopeptides metabolism, Prostatic Neoplasms therapy, Antigens, Surface, Carboxypeptidases immunology, Prostatic Neoplasms immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
The development of immunotherapy for cancer, such as synthetic peptide-based vaccines, relies heavily on the identification of appropriate epitopes capable of eliciting antitumor T-cell responses. We have used a combination of computer-based algorithms to predict peptide sequences from prostate-specific membrane antigen (PSMA) capable of stimulating in vitro CTLs restricted by the HLA-A2 MHC molecule. Four of the five peptides that were predicted by these algorithms were capable of inducing antigen-specific CTLs that killed target cells that were pulsed exogenously with the corresponding peptides. However, only one of the four peptides, PSMA(27), induced CTLs that were effective at recognizing prostate tumor cells expressing the HLA-A2 and PSMA molecules. These results underline the importance of demonstrating antitumor reactivity of peptide-induced CTLs for the selection of epitopes destined to become immunotherapeutic for prostate cancer.
- Published
- 2002
5. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen.
- Author
-
Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, and Colombatti M
- Subjects
- Antibodies, Monoclonal therapeutic use, Bone Neoplasms secondary, Carboxypeptidases immunology, Glutamate Carboxypeptidase II, Humans, Immunotoxins immunology, Male, Ricin administration & dosage, Tumor Cells, Cultured, Antigens, Surface, Carboxypeptidases pharmacology, Carcinoma pathology, Immunotoxins pharmacology, Prostatic Neoplasms pathology, Ricin pharmacology
- Abstract
Background: There is presently no effective therapy for relapsing, metastatic, androgen-independent prostate cancer. Immunotherapy with monoclonal antibody-vehicled toxins (Immunotoxins, ITs) may be a promising novel treatment option for the management of prostate cancer in these cases., Methods: Three anti-prostate specific membrane antigen (anti-PSMA) monoclonals (J591, PEQ226.5, and PM2P079.1) were cross-linked to ricin A-chain (RTA; native or recombinant), and their cytotoxic effects were investigated in monolayer and three-dimensional (3-D) cell cultures of prostate carcinoma cells (LNCaP)., Results: The various Immunotoxins showed effects in the nanomolar range (IC(50s) of 1.6-99 ng/ml) against PSMA+ cells (IC(50) being the concentration inhibiting 50% cell proliferation or protein synthesis). PSMA(-) cell lines were 62- to 277-fold less sensitive to anti-PSMA ITs, evidencing an appreciable therapeutic window. Treatment with J591-smpt-nRTA (0.35-31.7ng/ml) resulted in complete eradication of 3-D tumor micromasses or in 1.46- to 0.35-log reduction of target cells number, depending on the dose., Conclusion: Anti-PSMA ITs appear to be promising for use in the eradication of small prostate tumor cell aggregates present in tissues and in the bone marrow., (Copyright 2002 Wiley-Liss, Inc.)
- Published
- 2002
- Full Text
- View/download PDF
6. Ins and outs of clinical trials with peptide-based vaccines.
- Author
-
Salit RB, Kast WM, and Velders MP
- Subjects
- Animals, Carboxypeptidases immunology, Carcinoembryonic Antigen immunology, Clinical Trials as Topic, Glutamate Carboxypeptidase II, Humans, Mucin-1 immunology, Neoplasms immunology, Oncogene Protein p21(ras) immunology, Oncogene Proteins, Viral immunology, Papillomavirus E7 Proteins, Receptor, ErbB-2 immunology, Antigens, Surface, Cancer Vaccines immunology, Neoplasms prevention & control, Peptide Fragments immunology
- Abstract
Peptides are the smallest antigenic components that are recognized by T cells when presented in MHC molecules on the cell surface. After the identification of peptides from tumor associated and tumor specific antigens, the exploration of the use of peptides in immunotherapy of cancer was instigated. From initial exploration of peptide-mediated induction of immune responses in mice, the peptide based vaccines have evolved to clinical testing in cancer patients. Many different clinical trials have been performed to address the ability of peptide-based vaccines to induce both clinical and immunological responses in patients. This review will provide an overview of the results of the majority of the clinical trials with peptide-based vaccines directed against various antigens in patients with solid tumors.
- Published
- 2002
- Full Text
- View/download PDF
7. [Cloning and expression of extracellular domain of prostate specific membrane antigen in Escherichia coli and preparation of polyclonal antibody].
- Author
-
Ye CZ, Zhao XD, Zhang FL, Lin Z, Xu M, Zhang YK, and Chen CQ
- Subjects
- Animals, Antibody Formation, Carboxypeptidases genetics, Carboxypeptidases immunology, Carboxypeptidases isolation & purification, Chromatography, Affinity methods, Cloning, Molecular, DNA, Complementary genetics, Escherichia coli genetics, Genetic Vectors, Glutamate Carboxypeptidase II, Humans, Mice, Mice, Inbred BALB C, Protein Structure, Tertiary genetics, Protein Structure, Tertiary physiology, Recombinant Fusion Proteins biosynthesis, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins immunology, Recombinant Fusion Proteins isolation & purification, Reverse Transcriptase Polymerase Chain Reaction instrumentation, Antibodies immunology, Antigens, Surface, Carboxypeptidases biosynthesis, Gene Expression
- Abstract
Human Prostate Specific Membrane Antigen(PSMA) cDNA was amplified using total RNA extracted from prostate carcinoma tissue by RT-PCR. The cDNA fragment of extracellular domain of PSMA(edPSMA) gene was amplified by PCR and cloned into expression vector pMAL-c2x. Sequence analysis of both PSMA and edPSMA revealed identity to the GenBank reported. The edPSMA was expressed in E. coli as part of a fusion protein with MBP as the induction of IPTG. Western blot analysis showed the recombinant protein could react with PSMA monocloned antibodies 4G5. MBP-edPSMA fusion protein were purified by amylose resin affinity chromatography and showed to be homogeneity in SDS-PAGE(120 kD). BALB/C mice were immunized with the purified protein for the preparation of polyclonal antibody. The polyclonal antibody, which had a title of 1:12,800, were indicated the specificity to prostate tissue.
- Published
- 2002
8. [Active specific immune therapy of prostate gland cancer].
- Author
-
Chakŭrov S and Minchev M
- Subjects
- Glutamate Carboxypeptidase II, Granulocyte-Macrophage Colony-Stimulating Factor immunology, Granulocyte-Macrophage Colony-Stimulating Factor therapeutic use, Humans, Male, Prostatic Neoplasms immunology, Vaccines, DNA immunology, Vaccines, DNA therapeutic use, Antigens, Surface, Carboxypeptidases immunology, Dendritic Cells immunology, Immunotherapy, Adoptive methods, Prostatic Neoplasms therapy
- Published
- 2002
9. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma.
- Author
-
Chang SS, Reuter VE, Heston WD, and Gaudin PB
- Subjects
- Glutamate Carboxypeptidase II, Humans, Immunohistochemistry, Male, Paraffin Embedding, Prostatic Neoplasms immunology, Antibodies, Monoclonal, Antigens, Surface, Biomarkers, Tumor immunology, Carboxypeptidases immunology, Prostatic Neoplasms pathology
- Abstract
Objectives: To compare the immunohistochemical properties of the 7E11 anti-prostate-specific membrane antigen (anti-PSMA) monoclonal antibody (mAb) with the recently developed anti-PSMA mAb, PM2J004.5, and with other common immunomarkers in metastatic prostate cancer. PSMA is a type II integral membrane glycoprotein highly expressed in prostate cancer cells. The mAb 7E11 is currently used in the radioisotopic evaluation of prostate cancer, and its immunohistochemical properties have been examined in primary prostate cancer specimens., Methods: We examined 23 formalin-fixed, paraffin-embedded, metastatic prostate carcinoma specimens from various anatomic sites, including bone, lymph node, liver, lung, and soft tissue. Using the biotin-streptavidin method, we performed immunohistochemical reactions with the anti-PSMA mAbs 7E11 and PM2J004.5 and with antibodies to prostate-specific antigen and prostatic acid phosphatase. The immunoreactions were scored by pathologists unaware of the clinical and pathologic data according to a staining intensity scale and the percentage of cells stained., Results: All four mAbs consistently stained the metastatic prostate cancer specimens. In 2 (8.7%) of 23 cases, however, the prostate-specific antigen immunoreaction was negative but the anti-PSMA mAbs had positive staining. Although 7E11 and PM2J004.5 had a similar staining intensity and percentage of cells stained for most specimens, in 3 (13%) of 23 specimens, 7E11 had less intense staining. None of the specimens were negative for all four antibodies., Conclusions: Anti-PSMA mAbs consistently immunoreacted with metastatic prostate cancer specimens and were positive in instances when prostate-specific antigen staining was negative. The anti-PSMA mAbs demonstrated similar staining patterns; however, in select cases, the PM2J004.5 mAb did show more intense staining. The anti-PSMA mAbs 7E11 and PM2J004.5 are useful in the pathologic evaluation of paraffin-embedded metastatic prostate cancer specimens.
- Published
- 2001
- Full Text
- View/download PDF
10. PROSTASCINT scan for staging prostate cancer.
- Author
-
Lange PH
- Subjects
- Carboxypeptidases immunology, Glutamate Carboxypeptidase II, Humans, Lymph Node Excision, Male, Neoplasm Recurrence, Local diagnostic imaging, Prostate-Specific Antigen analysis, Prostatectomy, Radionuclide Imaging, Sensitivity and Specificity, Antibodies, Monoclonal, Antigens, Surface, Indium Radioisotopes, Prostatic Neoplasms diagnostic imaging, Radioimmunotherapy methods
- Published
- 2001
- Full Text
- View/download PDF
11. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
- Author
-
Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, Bander NH, Scheinberg DA, and Sgouros G
- Subjects
- Alpha Particles therapeutic use, Antibodies, Monoclonal immunology, Antibodies, Monoclonal metabolism, Antibodies, Monoclonal pharmacology, Cell Division radiation effects, Glutamate Carboxypeptidase II, Humans, Immunotoxins immunology, Immunotoxins metabolism, Male, Microscopy, Confocal, Neoplasm Metastasis, Prostatic Neoplasms immunology, Radioimmunotherapy, Spheroids, Cellular immunology, Spheroids, Cellular radiation effects, Tumor Cells, Cultured, Antigens, Surface, Bismuth pharmacology, Carboxypeptidases immunology, Immunotoxins pharmacology, Prostatic Neoplasms radiotherapy, Radioisotopes pharmacology
- Abstract
A theoretical drawback to alpha-particle therapy with 213Bi is the short range of the particle track coupled with the short half-life of the radionuclide, thereby potentially limiting effective cytotoxicity to rapidly accessible, disseminated individual tumor cells (e.g., as in leukemia). In this work, a prostate carcinoma spheroid model was used to evaluate the feasibility of targeting micrometastatic clusters of tumor cells using 213Bi-labeled anti-prostate-specific membrane antigen (PSMA) antibody, J591. In prostate cancer, vascular dissemination of tumor cells or tumor cell clusters to the marrow constitutes an important step in the progression of this disease to widespread skeletal involvement, an incurable state. Such prevascularized clusters are ideal targets for radiolabeled antibodies because the barriers to antibody penetration that are associated with the capillary basal lamina have not yet formed. Beta- and gamma-emitting radionuclides such as 131I, which are widely used in radioimmunotherapy, are not expected to be effective when targeting single cells or small cell clusters. This is because the range of the emissions is one to two orders of magnitude greater than the target size, and the energy deposited per traversal is insufficient to produce any significant radiobiological effect. Spheroids of the prostate cancer cell line, LNCaP-LN3, were used as a model of prevascularized micrometastases; their response to an anti-PSMA antibody, J591, radiolabeled with the alpha-particle emitter 213Bi (T(1/2), 45.6 min.) has been measured. The time course of spheroid volume reductions was found to be sensitive to the initial spheroid volume. J591 labeled with 0.9 MBq/ml 213Bi resulted in a 3-log reduction in spheroid volume on day 33, relative to control, for spheroids with an initial diameter of 130 microm; 1.8 MBq/ml were required to achieve a similar response for spheroids with an initial diameter of 180 microm. Equivalent spheroid responses were observed after 12 Gy of acute external beam photon irradiation. Monte Carlo-based microdosimetric analyses of the 213Bi decay distribution in individual spheroids of 130-microm diameter yielded an average alpha-particle dose of 3.7 Gy to the spheroids, resulting in a relative biological effectiveness factor of 3.2 over photon irradiation. The activity concentrations used in the experiments were clinically relevant, and this work supports the possibility of using 213Bi-labeled antibodies not only for disseminated single tumor cells, as found in patients with leukemia, but also for micrometastatic tumor deposits up to 180 microm in diameter (1200 cells).
- Published
- 2001
12. Indium-111-capromab pendetide scans: an important test relevant to clinical decision making.
- Author
-
Sartor O and McLeod D
- Subjects
- Carboxypeptidases immunology, Decision Making, Glutamate Carboxypeptidase II, Humans, Lymph Node Excision, Lymph Nodes diagnostic imaging, Lymphatic Metastasis diagnostic imaging, Male, Neoplasm Recurrence, Local diagnostic imaging, Odds Ratio, Predictive Value of Tests, Prognosis, Prostate-Specific Antigen analysis, Prostatectomy, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms secondary, Radionuclide Imaging, Antibodies, Monoclonal, Antigens, Surface, Indium Radioisotopes, Prostatic Neoplasms diagnostic imaging
- Published
- 2001
- Full Text
- View/download PDF
13. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
- Author
-
Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, and Bander NH
- Subjects
- Antibodies, Monoclonal metabolism, Antibodies, Monoclonal pharmacokinetics, Antibody Specificity, Antigens, Neoplasm metabolism, Antigens, Surface metabolism, Binding, Competitive, Carboxypeptidases metabolism, Cell Membrane metabolism, Chelating Agents pharmacokinetics, Drug Stability, Glutamate Carboxypeptidase II, Humans, Immunoconjugates metabolism, Immunoconjugates pharmacokinetics, Indium Radioisotopes, Isotope Labeling, Kinetics, Male, Prostatic Neoplasms immunology, Prostatic Neoplasms metabolism, Protein Structure, Tertiary, Quality Control, Tumor Cells, Cultured, Antibodies, Monoclonal immunology, Antigens, Neoplasm immunology, Antigens, Surface immunology, Carboxypeptidases immunology, Immunoconjugates immunology, Iodine Radioisotopes therapeutic use
- Abstract
Prostate-specific membrane antigen (PSMA) is a well-characterized cell surface antigen expressed by virtually all prostate cancers (PCas). PSMA has been successfully targeted in vivo with (111)In-labeled 7E11 monoclonal antibody (mAb; ProstaScint; Cytogen, Princeton, NJ), which binds to an intracellular epitope of PSMA. This work reports the in vitro characterization of three recently developed mAbs that bind the extracellular domain of PSMA (PSMAext). Murine mAbs J415, J533, J591, and 7E11 were radiolabeled with 131I and evaluated in competitive and saturation binding studies with substrates derived from LNCaP cells. J415 and J591 were conjugated to 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid labeled with (111)In. The uptake and cellular processing of these antibodies were evaluated in viable LNCaP cells. All four mAbs could be labeled with 131I up to a specific activity of 350 MBq/mg with no or little apparent loss of immunoreactivity. Competition assays revealed that J415 and J591 compete for binding to PSMAext antigen. J533 bound to a region close to the J591 binding epitope, but J533 did not interfere with J415 binding to PSMA. mAb 7E11 did not inhibit the binding of J415, J533, or J591 (or vice versa), consistent with earlier work that these latter mAbs bind PSMAext whereas 7E11 binds the intracellular domain of PSMA. Saturation binding studies demonstrated that J415 and J591 bound with a similar affinity (Kds 1.76 and 1.83 nM), whereas J533 had a lower affinity (Kd, 18 nM). In parallel studies, all four mAbs bound to a similar number of PSMA sites expressed by permeabilized cells (1,000,000-1,300,000 sites/cell). In parallel studies performed with viable LNCaP cells, J415, J533, and J591 bound to a similar number of PSMA sites (i.e., 600,000-800,000 sites/cell), whereas 7E11 bound only to a subpopulation of the available PSMA sites (95,000 sites/cell). This apparent binding of 7E11 to viable cells can be accounted for by a 5-7% subpopulation of permeabilized cells produced when the cells were trypsinized and suspended. Up to five DOTA chelates could be bound to either J415 or J591 without compromising immunoreactivity. A comparison of the cellular uptake and metabolic processing of the 131I- and (111)In-labeled antibodies showed a rapid elimination of 131I from the cell and a high retention of (111)In. All four mAbs recognized and bound to similar numbers of PSMAs expressed by ruptured LNCaP cells (i.e., the exposed intracellular and extracellular domains of PSMA). By comparison to J415 and J591, J533 had a lower binding affinity. Both J415 and J591 recognized and bound to the same high number of PSMAs expressed by intact LNCaP. By contrast, 7E11 bound to fewer sites expressed by intact LNCaP cells (i.e., the exposed extracellular domain of PSMA). Both J415 and J591 are promising mAbs for the targeting of viable PSMA-expressing tissue with diagnostic and therapeutic metallic radionuclides.
- Published
- 2000
14. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
- Author
-
Tino WT, Huber MJ, Lake TP, Greene TG, Murphy GP, and Holmes EH
- Subjects
- Animals, Antibodies, Monoclonal metabolism, Blotting, Western, Carboxypeptidases chemistry, Carboxypeptidases metabolism, Enzyme-Linked Immunosorbent Assay, Epitopes analysis, Female, Glutamate Carboxypeptidase II, Humans, Hybridomas, Immunoglobulin G analysis, Male, Mice, Mice, Inbred A, Mice, Inbred BALB C, Organ Specificity immunology, Prostate enzymology, Prostatic Neoplasms immunology, Protein Conformation, Protein Denaturation, Tumor Cells, Cultured, Antibodies, Monoclonal chemistry, Antibodies, Monoclonal isolation & purification, Antibody Specificity, Antigens, Surface, Carboxypeptidases immunology, Epitopes immunology, Prostate immunology
- Abstract
Prostate-specific membrane antigen (PSMA) is a 750-amino acid glycoprotein highly expressed in malignant prostate tissues. PSMA reacts with the murine monoclonal antibody 7E11.C5, whose binding epitope has been mapped to the N-terminal of the protein distributed on the cytoplasmic side of the plasma membrane. We have developed murine monoclonal antibodies specific for extracellular epitopes of PSMA. Three of these antibodies--1G9, 3C6, and 4D4--display distinct binding properties consistent with their recognition of conformational epitopes within native PSMA. Results indicate this panel of antibodies binds to native full-length PSMA, but not to fusion proteins containing portions of the linear sequence of the protein. Antibody binding is greatly reduced upon heat denaturation of native PSMA, and these antibodies do not detect PSMA by Western blot. Immunoprecipitation experiments demonstrate the ability of each to bind to full-length PSMA as well as PSM', a form of the protein missing the first 57 amino acids. These results indicate each antibody is specific for an epitope within the extracellular domain, a region spanning residues 44-750. Flow cytometric experiments indicate strong specific binding to live LNCaP cells. Antibody inhibition studies demonstrate that these antibodies recognize at least two distinct epitopes. Taken together, the results demonstrate that these antibodies are specific for native protein conformational epitopes within the extracellular domain. Their properties, in particular strong binding to live cancer cells, make them ideal candidates that are clearly superior to linear sequence epitope specific antibodies for in vivo applications.
- Published
- 2000
- Full Text
- View/download PDF
15. Serum levels of PSMA.
- Author
-
Murphy GP, Su S, Jarisch J, and Kenny GM
- Subjects
- Antibodies, Monoclonal immunology, Blotting, Western methods, Carboxypeptidases immunology, Glutamate Carboxypeptidase II, Humans, Male, Sensitivity and Specificity, Antigens, Surface, Carboxypeptidases blood, Prostatic Neoplasms immunology
- Published
- 2000
- Full Text
- View/download PDF
16. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial.
- Author
-
Lodge PA, Jones LA, Bader RA, Murphy GP, and Salgaller ML
- Subjects
- Carboxypeptidases immunology, Glutamate Carboxypeptidase II, Humans, Hypersensitivity, Delayed etiology, Immunocompetence, Interferon-gamma biosynthesis, Male, Prostatic Neoplasms immunology, Antigens, Surface, Dendritic Cells immunology, Immunotherapy, Adoptive, Prostatic Neoplasms therapy
- Abstract
We assessed both non- and peptide-specific immune responses in prostate cancer patients before and after immunotherapy with dendritic cells exogenously pulsed with the prostate-specific membrane antigen-derived peptides, PSM-P1 and PSM-P2. For all subjects, we observed that clinical responses were strongly associated with two indicators of immunocompetence: skin test responses to recall antigens and cytokine secretion by T cells after nonspecific stimulation. In a subset of responders, we observed cytokine secretion or cytotoxicity against the immunizing peptides or an immunodominant epitope from an influenza recall antigen. The clinical results support the use of monitoring for overall immunocompetence to help determine why a patient has or has not responded to therapy. Moreover, it could be useful as an inclusion criterion to select those more likely to benefit from treatment.
- Published
- 2000
17. Tumor vaccines for the management of prostate cancer.
- Author
-
McNeel DG and Disis ML
- Subjects
- Acid Phosphatase immunology, Animals, Antigens, Tumor-Associated, Carbohydrate immunology, Carboxypeptidases immunology, Dendritic Cells immunology, Disease Models, Animal, Glutamate Carboxypeptidase II, Humans, Male, Mice, Neoplasms, Experimental immunology, Neoplasms, Experimental therapy, Prostate-Specific Antigen immunology, Prostatic Neoplasms immunology, Rats, Antigens, Surface, Cancer Vaccines therapeutic use, Prostatic Neoplasms therapy
- Abstract
Prostate cancer is a significant health problem and one of the leading causes of cancer-related death among men. Given the typically long natural history of the disease, there is considerable interest in developing new therapies to treat or prevent metastatic disease, and cancer vaccines are a particularly attractive immune-based approach. Early clinical studies using non-specific immunomodulatory treatments have met with limited success, but also suggest that improved immunologic approaches might be useful in treating human prostate cancer. Over the last decade, the identification of immune cells responsible for actual destruction of prostate tissue and advances in immunologic and molecular techniques have led to a variety of vaccination approaches that are currently being evaluated in human clinical trials. The present article discusses the rationale in animal models for particular immunization strategies and describes the vaccines currently being used in patients with prostate cancer. The ongoing identification of tumor antigens and proteins involved in prostate cancer progression and the development of better immunologic animal models suggest a hopeful future for the design of effective prostate cancer vaccines.
- Published
- 2000
18. PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response.
- Author
-
Zhu ZY, Zhong CP, Xu WF, Lin GM, Ye GQ, Ji YY, Sun B, and Yeh M
- Subjects
- Animals, Antigens, Neoplasm isolation & purification, Carboxypeptidases isolation & purification, Chromatography, Affinity, Epitopes, B-Lymphocyte immunology, Glutamate Carboxypeptidase II, Humans, Male, Mice, Mice, Inbred C57BL, Molecular Mimicry, Peptide Library, Prostate-Specific Antigen analysis, Prostatic Neoplasms chemistry, Prostatic Neoplasms immunology, Sequence Analysis, Antigens, Neoplasm immunology, Antigens, Surface, Carboxypeptidases immunology, Prostate-Specific Antigen immunology
- Abstract
Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein expressed predominantly in prostate secretory acinar epithelium and prostate cancer cells as well as in several extraprostatic tissues. Mouse monoclonal antibody 4G5 specific to the extracellular domain of PSMA was used to screen two phage displayed peptide libraries (9aa linear and 9aa cys library). Three 4G5-reactive phagotopes were identified. Sequence analysis of isolated clones demonstrated that the interaction motif "VDPA/SK" has high homology to 719-725aa on PSMA. Immunohistochemical staining of the prostate cancer sample with the PSMA-mimic phagotope (mimotope) immunized serum antibodies demonstrate that the mimotope isolated from the phage displayed peptide libraries can induce PSMA specific immune response in vivo.
- Published
- 1999
- Full Text
- View/download PDF
19. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
- Author
-
Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, and Gaudin PB
- Subjects
- Antibodies, Monoclonal, Antigens, Neoplasm analysis, Antigens, Neoplasm genetics, Breast Neoplasms blood supply, Breast Neoplasms enzymology, Breast Neoplasms pathology, Carboxypeptidases immunology, Carcinoma, Renal Cell blood supply, Carcinoma, Renal Cell enzymology, Carcinoma, Renal Cell pathology, Female, Glutamate Carboxypeptidase II, Humans, Male, Neoplasms pathology, Prostatic Neoplasms blood supply, Prostatic Neoplasms enzymology, Prostatic Neoplasms pathology, Testicular Neoplasms blood supply, Testicular Neoplasms enzymology, Testicular Neoplasms pathology, Transfection, Tumor Cells, Cultured, Urinary Bladder Neoplasms blood supply, Urinary Bladder Neoplasms enzymology, Urinary Bladder Neoplasms pathology, Antigens, Surface, Carboxypeptidases analysis, Carboxypeptidases genetics, Neoplasms blood supply, Neoplasms enzymology, Neovascularization, Pathologic enzymology, Prostate enzymology
- Abstract
Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein that was initially characterized by the monoclonal antibody (mAb) 7E11. PSMA is highly expressed in prostate secretory-acinar epithelium and prostate cancer as well as in several extraprostatic tissues. Recent evidence suggests that PSMA is also expressed in tumor-associated neovasculature. We examined the immunohistochemical characteristics of 7E11 and those of four recently developed anti-PSMA mAbs (J591, J415, and Hybritech PEQ226.5 and PM2J004.5), each of which binds a distinct epitope of PSMA. Using the streptavidin-biotin method, we evaluated these mAbs in viable prostate cancer cell lines and various fresh-frozen benign and malignant tissue specimens. In the latter, we compared the localization of the anti-PSMA mAbs to that of the anti-endothelial cell mAb CD34. With rare exceptions, all five anti-PSMA mAbs reacted strongly with the neovasculature of a wide spectrum of malignant neoplasms: conventional (clear cell) renal carcinoma (11 of 11 cases), transitional cell carcinoma of the urinary bladder (6 of 6 cases), testicular embryonal carcinoma (1 of 1 case), colonic adenocarcinoma (5 of 5 cases), neuroendocrine carcinoma (5 of 5 cases), glioblastoma multiforme (1 of 1 cases), malignant melanoma (5 of 5 cases), pancreatic duct carcinoma (4 of 4 cases), non-small cell lung carcinoma (5 of 5 cases), soft tissue sarcoma (5 of 6 cases), breast carcinoma (5 of 6 cases), and prostatic adenocarcinoma (2 of 12 cases). Localization of the anti-PSMA mAbs to tumor-associated neovasculature was confirmed by CD34 immunohistochemistry in sequential tissue sections. Normal vascular endothelium in non-cancer-bearing tissue was consistently PSMA negative. The anti-PSMA mAbs reacted with the neoplastic cells of prostatic adenocarcinoma (12 of 12 cases) but not with the neoplastic cells of any other tumor type, including those of benign and malignant vascular tumors (0 of 3 hemangiomas, 0 of 1 hemangioendothelioma, and 0 of 1 angiosarcoma). The mAbs to the extracellular PSMA domain (J591, J415, and Hybritech PEQ226.5) bound viable prostate cancer cells (LNCaP and PC3-PIP), whereas the mAbs to the intracellular domain (7E11 and Hybritech PM2J004.5) did not. All five anti-PSMA mAbs reacted with fresh-frozen benign prostate secretory-acinar epithelium (28 of 28 cases), duodenal columnar (brush border) epithelium (11 of 11 cases), proximal renal tubular epithelium (5 of 5 cases), colonic ganglion cells (1 of 12 cases), and benign breast epithelium (8 of 8 cases). A subset of skeletal muscle cells was positive with 7E11 (7 of 7 cases) and negative with the other four anti-PSMA mAbs. PSMA was consistently expressed in the neovasculature of a wide variety of malignant neoplasms and may be an effective target for mAb-based antineovasculature therapy.
- Published
- 1999
20. Follow-up evaluation of a phase II prostate cancer vaccine trial.
- Author
-
Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, and Murphy GP
- Subjects
- Carboxypeptidases immunology, Dendritic Cells immunology, Glutamate Carboxypeptidase II, HLA-A2 Antigen immunology, Humans, Immunotherapy, Adoptive, Leukapheresis, Male, Prostate-Specific Antigen blood, Prostatic Neoplasms immunology, Antigens, Surface, Cancer Vaccines therapeutic use, Immunotherapy, Prostatic Neoplasms therapy
- Abstract
Background: A phase II trial, involving infusions of autologous dendritic cells (DC) and two human histocompatibility antigen (HLA-A2)-specific prostate-specific membrane antigen (PSMA) peptides, was recently completed. Thirty percent of the participants, including subjects with hormone-refractory metastastic disease, and those with suspected local recurrence of prostate cancer, were identified as clinical responders. This report describes the follow-up evaluation of 19 responders in the two study groups., Methods: After conclusion of the study, study participants were subjected to follow-up evaluations at 6-8-week intervals. Each responder was reevaluated for response status, and duration of response was determined., Results: Subjects were observed for an average of 291 days (metastastic group, group A-2) and 557 days (local recurrence group, group B), which included the treatment and follow-up periods. The average duration of response was 149 days for group A-2, and 187 days for group B. A majority of responders (11/19; 58%) were still responsive at the end of the current follow-up., Conclusions: The responses observed may be significant and relatively durable. This study suggests that DC-based cancer vaccines in the future may provide an additional therapy for advanced prostate cancer.
- Published
- 1999
- Full Text
- View/download PDF
21. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.
- Author
-
Gong MC, Chang SS, Sadelain M, Bander NH, and Heston WD
- Subjects
- Antibody Specificity, Antigens, Neoplasm immunology, Glutamate Carboxypeptidase II, Humans, Immunohistochemistry, Male, Neoplasms diagnosis, Antibodies, Monoclonal therapeutic use, Antigens, Surface, Carboxypeptidases immunology, Neoplasms drug therapy, Prostatic Neoplasms diagnosis, Prostatic Neoplasms drug therapy
- Abstract
Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein that is expressed by prostate epithelial cells. PSMA-specific monoclonal antibodies have been utilized to characterize the biologic function and in vivo biodistribution of PSMA. PSMA is an attractive target protein for monoclonal antibody directed imaging or therapeutics for prostate cancer since its expression is relatively restricted to prostate epithelial cells and is over-expressed in prostate cancer, including in advanced stages. Currently, clinical usage of PSMA specific monoclonal antibodies has been limited to diagnostic immunohistochemistry and imaging of patients with prostate cancer. Novel applications for these antibodies will be discussed.
- Published
- 1999
- Full Text
- View/download PDF
22. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells.
- Author
-
Corman JM, Sercarz EE, and Nanda NK
- Subjects
- Adult, Amino Acid Sequence, Cells, Cultured, Epitope Mapping, Glutamate Carboxypeptidase II, HLA-DR4 Antigen immunology, Humans, Male, Molecular Sequence Data, Antigens, Surface, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Carboxypeptidases immunology, Epitopes, T-Lymphocyte immunology, Prostate-Specific Antigen immunology
- Abstract
It is now becoming accepted that one is not tolerant to all the determinants of self proteins: the T cell repertoire directed to some sequences in self proteins is intact and can be activated. When a self protein is exclusively expressed by tumour cells, the T cell repertoire directed to the particular self antigen can potentially be activated to attack the tumour: this would amount to induction of a beneficial autoimmune response. Prostate cancer offers a unique opportunity for activation of a tumour-specific immune response owing to the exclusive synthesis of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSM) by prostatic tissue and prostate tumour cells. In this study we examine the CD4 and CD8 T cell repertoires specific for peptides of PSA and PSM in normal human male individuals, using short-term, peptide antigen-driven CD4 and CD8 T cell lines. We show that short-term, CD4 T cell lines derived from six HLA-DR4 individuals showed strong proliferative responses to six of 10 tested peptides of PSA, selected as to contain a DR4 binding motif. Short-term, CD8 T cell lines from three HLA-A1 individuals showed specific cytolytic activity for autologous targets loaded with five of five tested peptides of PSA and PSM, selected to possess an HLA-A1 binding motif. One of the peptides chosen is termed a 'dual-motif' peptide, as it encodes determinants for both CD4 and CD8 T cells. These results, indicating the existence of CD4 and CD8 T cells against determinants of the self proteins, PSA and PSM, in healthy male individuals reveal the potential of the T cell repertoire from the typical prostate cancer patient to eradicate prostate tumours upon being appropriately activated.
- Published
- 1998
- Full Text
- View/download PDF
23. High level expression and secretion of Fc-X fusion proteins in mammalian cells.
- Author
-
Lo KM, Sudo Y, Chen J, Li Y, Lan Y, Kong SM, Chen L, An Q, and Gillies SD
- Subjects
- Animals, Antibodies, Monoclonal biosynthesis, Carboxypeptidases immunology, Culture Media, Conditioned, Dimerization, Dipeptidyl Peptidase 4 metabolism, Disulfides metabolism, Genetic Vectors, Glutamate Carboxypeptidase II, Glycosylation, Humans, Immunoglobulin Fc Fragments immunology, Immunoglobulin gamma-Chains genetics, Immunoglobulin kappa-Chains genetics, Mice, Mutagenesis, Restriction Mapping, Transfection, Tumor Cells, Cultured, Antigens, Surface, Gene Expression, Immunoglobulin Fc Fragments genetics, Protein Sorting Signals genetics, Recombinant Fusion Proteins
- Abstract
We have developed a general expression system that enhances the production and secretion of proteins in mammalian cells. The protein of interest is expressed as a fusion to a signal peptide and the Fc fragment of immunoglobulin as the N-terminal fusion partner, which can direct the cellular processes into expressing and secreting high levels of many different types of proteins. These include secretory proteins, enzymes and soluble domains of membrane proteins, as well as nuclear and regulatory proteins. Typical expression levels of these proteins from stable cell lines ranged from several to 100 microg/ml in conditioned media. The Fc domain helps to solubilize hydrophobic proteins and provides a handle for easy detection and purification of the fusion proteins; and it can be cleaved off by treatment with protease if desired.
- Published
- 1998
- Full Text
- View/download PDF
24. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
- Author
-
Murphy GP, Kenny GM, Ragde H, Wolfert RL, Boynton AL, Holmes EH, Misrock SL, Bartsch G, Klocker H, Pointner J, Reissigl A, McLeod DG, Douglas T, Morgan T, and Gilbaugh J Jr
- Subjects
- Antibodies, Monoclonal, Antigens, Neoplasm immunology, Antigens, Surface immunology, Blotting, Western, Carboxypeptidases immunology, Epitopes, Glutamate Carboxypeptidase II, Humans, Hybridomas, Male, Prognosis, Prostatic Hyperplasia blood, Prostatic Neoplasms therapy, Prostatitis blood, Radioimmunoassay, Tumor Cells, Cultured, Antigens, Neoplasm blood, Antigens, Surface blood, Biomarkers, Tumor blood, Carboxypeptidases blood, Prostatic Neoplasms diagnosis
- Abstract
Objectives: To describe current results with Western blot assay for prostate specific membrane antigen (PSMA) using 7E11.C5 antibody and the development of an additional antibody measurement for PSMA by a new sandwich immunoassay., Methods: A population of patients from a screening group, from a difficult diagnostic group, from a pre- and postoperative radical prostatectomy group, and from a group with metastatic disease followed for a serial period, provided the serum values for a prospective assessment of PSMA by Western blot assay. A new monoclonal antibody was sought, reacting to the C-terminal region of PSMA in order to develop a sandwich radioimmunoassay., Results: PSMA values in screened patients correlate with the more advanced stage of the cancers determined. In postprostatectomy patients, the PSMA value corresponds more with preoperative values and with the values of those with a poor clinical course. In difficult diagnostic cases, the PSMA value is increased, specifically in hormone-refractory cases and particularly in those cases judged by other criteria, such as the National Prostatic Cancer Project, to be in clinical progression compared with those judged to be in clinical remission. The level of PSMA value appears to be independent of homogeneous tumor volume and to be more related to that of prior hormone treatment, or to where prostate cancer cells can be documented to be outside the prostate. A new monoclonal antibody, 3F5.4G6, reacts with the extracellular domain of PSMA near the C-terminal region. This is in contrast to the previously measured antibody 7E11.C5, which reacts with an N-terminal epitope. 3F5.4G6 recognizes the same PSMA protein as does 7E11.C5. The epitopes are essentially at opposite ends of the molecule. The 3F5.4G6 antibody reacts with the LNCaP line but not with DU145, or PC3. These two antibodies to PSMA are well suited for use in a new sandwich immunoassay., Conclusions: PSMA provides a prostatic cancer serum test by using Western blot, which suggests a clinical prognostic value not seen with other markers. New antibodies, such as 3F5.4G6, reacting with the extracellular domain of PSMA combined with 7E11.C5, appear to offer an opportunity for a new sandwich immunoassay.
- Published
- 1998
- Full Text
- View/download PDF
25. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).
- Author
-
Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, and Murphy GP
- Subjects
- Enzyme-Linked Immunosorbent Assay, Genes, MHC Class I, Glutamate Carboxypeptidase II, Humans, Male, Treatment Outcome, Antigens, Neoplasm immunology, Antigens, Surface, Carboxypeptidases immunology, Dendritic Cells immunology, HLA-A Antigens immunology, Immunotherapy, Adoptive methods, Prostatic Neoplasms immunology, Prostatic Neoplasms therapy, T-Lymphocytes immunology
- Abstract
Background: In this paper we describe our program for the immune monitoring of phase II participants given dendritic cell (DC)/prostate-specific membrane antigen (PSMA)-based immunotherapy, and we also present some initial findings., Methods: Phase II subjects received six administrations of autologous dendritic cells exogenously pulsed with two peptides derived from PSMA. Prior to the initial infusion, and following each treatment, peripheral blood mononuclear cells (PBMC) were collected for the generation of dendritic cells as well as for comprehensive immune monitoring., Results: Thus far, an increase in PSMA-peptide-specific as well as overall cellular reactivity has been observed in several patients receiving DC plus PSM-P1 and -P2, as measured by delayed-type hypersensitivity (DTH) test and enzyme-linked immunosorbant assay (ELISA)., Conclusions: Our initial observations using an ELISA and DTH test indicate that we are enhancing cellular immunity in prostate cancer patients following infusion with DC plus PSMA-derived peptides. Several methods are underway to comprehensively monitor both cell-mediated and humoral immune responsiveness, including: determining anti-PSMA serum antibody titers, testing immunogen-restricted responder-cell proliferation and cytotoxicity, assessing aberrations in signal transduction, antigen processing, and presentation, and measuring soluble factors that may promote tumor outgrowth.
- Published
- 1998
- Full Text
- View/download PDF
26. Prostate-specific membrane antigen.
- Author
-
Maraj BH, Whelan P, and Markham AF
- Subjects
- Antibodies, Monoclonal analysis, Glutamate Carboxypeptidase II, Humans, Immunotherapy methods, Male, Polymerase Chain Reaction, Prostatic Neoplasms therapy, T-Lymphocytes immunology, Antigens, Surface, Carboxypeptidases genetics, Carboxypeptidases immunology, Carboxypeptidases metabolism, Prostatic Neoplasms diagnosis
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.